New artificial intelligence technology is helping diagnose the U.S.’s most deadly cancer sooner, greatly improving the ...
About 40% of people with non-small cell lung cancer (NSCLC)—a type of cancer that begins in the tissues of your lungs—have metastatic disease at the time of their diagnosis. Metastatic NSCLC refers to ...
When treated early, Stage 1 lung cancer patients have a five-year survival rate of above 70 per cent. Read more at straitstimes.com. Read more at straitstimes.com.
Amtagvi monotherapy achieved a 25.6% objective response rate and 71.8% disease control rate in NSCLC patients without ...
Results from a phase 1/2 clinical trial (NCT05099172) show the safety and efficacy of sevabertinib (BAY2927088) in patients with non–small cell lung cancer (NSCLC) harboring HER2 or EGFR mutations. 1 ...
October brought several updates in the lung cancer field, ranging from notable trial results to patient-centered perspectives ...
Compared to patients treated only with chemotherapy, the combination of an immunotherapy drug and chemotherapy almost doubled the survival time for some lung cancer patients, according to a study ...
Ask a clinical question and tap into Healio AI's knowledge base. Lung cancer is generally the top cause of cancer-related death globally and in the United States (US). In the US in 2023, lung cancer ...
Brachytherapy, a form of internal radiotherapy, has emerged as a promising treatment modality for patients with non-small cell lung cancer (NSCLC). This technique involves the precise implantation of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback